Poseida Therapeutics — Company Overview, News & Financial Data
Poseida Therapeutics is a biotech firm advancing CAR-T therapies and gene editing for cancer and rare diseases.
Poseida Therapeutics
Company profile
About Poseida Therapeutics
Poseida Therapeutics (NASDAQ:PSTX) is a biotechnology company focused on the development of innovative cell and gene therapies. Utilizing groundbreaking technology, Poseida seeks to engineer life-saving treatments for patients with cancer and rare diseases. The company's diverse pipeline includes unique approaches to CAR-T therapies for solid tumors and hematological malignancies, alongside cutting-edge gene editing technologies aimed at genetic disorders. With a commitment to advancing medicine and improving lives, Poseida Therapeutics is dedicated to pushing the boundaries of science to deliver new therapies that can address unmet medical needs.
Snapshot
2014Year founded
324Employees
San Diego, United StatesHead office
Loading Map...
Global footprint
Operations
All Locations
San Diego, US
Products and/or services of Poseida Therapeutics
- Novel gene therapies leveraging non-viral delivery platforms aimed at treating severe genetic diseases, focusing on high precision and safety.
- CAR-T programs targeting solid tumors and hematological malignancies, utilizing unique technology for enhanced cancer cell targeting.
- In-house T-cell engineering platform to develop off-the-shelf CAR-T therapies, reducing treatment time and cost for patients.
- Gene editing tools based on proprietary DNA-cutting enzymes, offering potential for correction of a wide array of genetic disorders.
- Liver-directed therapies using non-viral gene delivery techniques for treating metabolic diseases, focusing on improving efficacy and reducing adverse effects.
- Partnerships with major pharmaceutical companies to accelerate the development and commercialization of advanced therapies in areas of unmet medical need.
Poseida Therapeutics executive team
- Mr. Mark J. Gergen J.D.Executive Chairman of the Board
- Ms. Johanna M. Mylet CPAChief Financial Officer
- Mr. Loren WagnerChief Operations Officer
- Ms. Kristin MartinChief People & Administration Officer
- Mr. Alexander ChapmanSenior VP of Investor Relations & Corporate Communications
- Mr. Harry J. Leonhardt Esq., J.D.General Counsel, Chief Compliance Officer & Corporate Secretary
- Dr. Devon J. Shedlock Ph.D.Chief Scientific Officer of Cell Therapy
- Ms. Lisa PortaleSenior Vice President of Regulatory Affairs
- Dr. Jeffrey W. Winkelman J.D., Ph.D.Senior VP & Chief Patent Counsel
- Ms. Karen Basbaum M.B.A.Senior Vice President of Business Development
GET YOUR GRAFA EDGE NOW
Sign up free to follow this company
We'll switch on a 30-day Edge trial as a welcome gift